reports
- Maxim Jacobs
CollPlant Holdings - Enters into licensing and commercialisation agre...
In late October 2018, CollPlant and United Therapeutics (NASDAQ: UTHR) announced a licensing, development and commercialisation agreement for 3D bioprinted lung transplants using rhCollagen-based BioInk. This news follows the United Therapeutics’ Science Day in September, where its founder and CEO presented the company’s R&D using CollPlant’s rhCollagen to 3D bioprint lung scaffolds. This co-development agreement further validates CollPlant’s technology.
- Maxim Jacobs
CollPlant Holdings - Ongoing third-party interest in BioInk
CollPlant demonstrated another productive quarter with a 209% increase in reported revenue over the same period in 2017, mainly attributed to sales of its BioInk product in the US and its Vergenix product brands, primarily its VergenixSTR for tendinopathy, in Europe. The rhCollagen-based BioInk continues to demonstrate that it is a strategic area of development for CollPlant with repeat sales to third parties.
- Maxim Jacobs
CollPlant Holdings - A productive year to date
The year to date has been highly productive for CollPlant. It has completed a new production facility in Rehovot to support its increased commercial efforts. These include both its BioInk product for 3D bioprinting of organs and tissue, as well as VergenixFG and VergenixSTR for wound care and tendinopathy respectively, which are expanding operations in Europe. In addition, the company has announced its intention to de-list from TASE to trade exclusively on NASDAQ.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.